Month: November 2018
Congress’s health-care priorities are likely to focus on drug prices as Obamacare repeal becomes a non-starter for a split legislature, Senate Majority Leader Mitch McConnell said Wednesday.
“Anna” will not stop calling. She really, really wants to sell you health insurance. What a lot of consumers really, really want is to smack Anna upside her robocalling head.
California’s Medicaid program made at least $4 billion in questionable payments to health insurers and medical providers over a four-year period because as many as 453,000 people were ineligible for the public benefits, according to a state audit released Tuesday.
Congressional Report Says Insulin Market Benefits Drugmakers and Insurers, Not Patients
“Perverse” incentives in the insulin supply chain lead to artificially high prices, as well as limited competition in the markets, according to a bipartisan report released Thursday by two lawmakers.
U.S. health insurer Cigna Corp (CI.N), which is in the process of acquiring Express Scripts Holding Co (ESRX.O), significantly bumped up its 2018 adjusted profit forecast, and its shares rose more than 3 percent on Thursday.
Healthcare Waste is Costing Billions – and Clients Aren’t Doing Anything About It
Providing the workforce with healthcare coverage is expensive, but a new survey of 126 employers suggests a large chunk of that cost is being wasted by the healthcare industry on treatments patients don’t need.
8 Results We’re Watching on Election Day with big Healthcare Implications
Healthcare has been a central theme of the 2018 election, arguably more so than any other election in recent history.
Health Coverage Disparities Eliminated Under ACA for Most Racial Groups, Report Finds
African Americans, Asians and Pacific Islanders living in California are just as likely to have health insurance as whites, marking a significant turnaround from five years ago, new data shows.
Despite Criticism and Concerns, FDA Approves A New Opioid 10 Times More Powerful than Fentanyl
In a highly controversial move, the Food and Drug Administration approved an especially powerful opioid painkiller despite criticism that the medicine could be a “danger” to public health. And in doing so, the agency addressed wider regulatory thinking for endorsing such a medicine amid nationwide angst about overdoses and deaths attributed to opioids.